Maria Seliverstov, MD
Psychiatry · Sherman Oaks, CANPI 1457520009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 25.8% of the total. Reporting peaked in 2024 at $454 and has fallen 70.4% since, to $135 in 2025.
Across 47 payments — averaging $41.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$506
- AbbVie$375
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
- Otsuka America Pharmaceutical, Inc.$241
- Axsome Therapeutics, Inc.$135
- Idorsia Pharmaceuticals US Inc$115
- plus $338 from 5 others
Across 11 payments — averaging $28,690 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$227K
- E.r. Squibb & Sons, L.L.C.$65K
- Janssen Research & Development, LLC$24K
What the payments were for
- Food & beverage$1,960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 18 | $506 |
| AbbVie(2 entities) | 8 | $375 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $250 |
| Otsuka America Pharmaceutical, Inc. | 2 | $241 |
| Axsome Therapeutics, Inc. | 1 | $135 |
| Idorsia Pharmaceuticals US Inc | 1 | $115 |
| Lundbeck LLC | 5 | $99 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Sunovion Pharmaceuticals Inc. | 3 | $67 |
| Johnson & Johnson | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,960 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $137,742 |
| TrintellixVortioxetine Hydrobromide | 82 | $43,078 |
| FanaptIloperidone | 11 | $41,958 |
| VraylarCariprazine Hcl | 27 | $41,489 |
| RexultiBrexpiprazole | 15 | $30,287 |
| CaplytaLumateperone Tosylate | 11 | $20,841 |
| Aripiprazole | 160 | $14,863 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $12,725 |
| DayvigoLemborexant | 33 | $10,461 |
| Memantine Hcl ErMemantine Hcl | 66 | $8,052 |
| Rivastigmine | 22 | $5,365 |
| Memantine Hcl | 129 | $4,827 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 311 | $4,739 |
| Quetiapine Fumarate | 211 | $4,098 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 45 | $3,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $506 | $137,74217 claims |
| AbbVieVraylar, Namzaric | $375 | $54,21344 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $87 | $41,95811 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $241 | $30,28715 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $250 | $20,84111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Sherman Oaks
- Thomas ShiovitzSherman Oaks$151K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.